| 83.01 -1.68 (-1.98%) | 08-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 109.48 | 1-year : | 127.88 |
| Resists | First : | 93.73 | Second : | 109.48 |
| Pivot price | 83.22  |
|||
| Supports | First : | 79.56 | Second : | 70.8 |
| MAs | MA(5) : | 80.23 |
MA(20) : | 83.23 |
| MA(100) : | 75.9 |
MA(250) : | 59.34 |
|
| MACD | MACD : | 1 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 66 |
D(3) : | 46 |
| RSI | RSI(14): 51.9 |
|||
| 52-week | High : | 97.97 | Low : | 15.53 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SLGL ] has closed above bottom band by 48.7%. Bollinger Bands are 19.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 85.61 - 86.1 | 86.1 - 86.55 |
| Low: | 80.65 - 81.17 | 81.17 - 81.64 |
| Close: | 82.25 - 83.1 | 83.1 - 83.86 |
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Fri, 14 Aug 2026
Sol-Gel Technologies (SLGL) Projected to Announce Quarterly Earnings on Friday - marketbeat.com
Wed, 12 Aug 2026
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Average Rating of "Moderate Buy" by Brokerages - marketbeat.com
Mon, 10 Aug 2026
Sol Gel Technologies Ltd (SLGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mon, 27 Jul 2026
Sol Gel Technologies Ltd (SLGL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sat, 25 Jul 2026
Affinity Asset Advisors LLC Purchases Shares of 35,000 Sol-Gel Technologies Ltd. $SLGL - marketbeat.com
Thu, 25 Jun 2026
SLGL Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 530070 (%) |
| Held by Institutions | 59.7 (%) |
| Shares Short | 52 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.3e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -5.7 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 569.4 % |
| Return on Equity (ttm) | -3.5 % |
| Qtrly Rev. Growth | 1.846e+007 % |
| Gross Profit (p.s.) | -77.16 |
| Sales Per Share | -2.52 |
| EBITDA (p.s.) | 1.48276e+006 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -32.98 |
| Price to Cash Flow | 6.12 |
| Dividend | 0 |
| Forward Dividend | 46650 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|